1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,760 | 1,820 | 14:40 | |
| 1,760 | 1,820 | 14:31 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.10. | Aclarion, Inc.: Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026 | 1 | GlobeNewswire (USA) | ||
| 13.10. | Aclarion, Inc.: Aclarion to Present at the 20th Annual LD Micro Main Event | 1 | GlobeNewswire (USA) | ||
| 08.10. | Aclarion, Inc.: Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment | 324 | GlobeNewswire (Europe) | New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment paceInitial readout timing to be updated by year-end based on demonstrated Q4 enrollment... ► Artikel lesen | |
| 29.09. | Aclarion, Inc.: Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites | 1 | GlobeNewswire (USA) | ||
| 20.08. | Aclarion adds University of Arizona to Nociscan spine trial | 1 | Investing.com | ||
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 12.08. | Aclarion, Inc.: Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process | 467 | GlobeNewswire (Europe) | Patent protects the precision of MRS data capture within the target disc - a critical step in the Nociscan workflowDesigned to reduce scan time, support faster technologist onboarding and deliver... ► Artikel lesen | |
| 06.08. | Aclarion, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | Aclarion, Inc.: Aclarion Announces Nociscan Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology | 1 | GlobeNewswire (USA) | ||
| 29.07. | Aclarion: Scan-Volumen im ersten Halbjahr 2026 um 141 % gestiegen | 3 | Investing.com Deutsch | ||
| 29.07. | Aclarion, Inc.: Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 | 600 | GlobeNewswire (Europe) | 141% year-over-year scan volume growth in first half of 2026Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA... ► Artikel lesen | |
| 09.07. | Aclarion, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 07.07. | Aclarion adds Texas Spine Care Center to CLARITY trial | 1 | Investing.com | ||
| 07.07. | Aclarion erweitert CLARITY-Studie um Texas Spine Care Center | 2 | Investing.com Deutsch | ||
| 07.07. | Aclarion, Inc.: Aclarion Announces Texas Spine Care Center as New CLARITY Site | 1 | GlobeNewswire (USA) | ||
| 10.06. | Aclarion, Inc.: Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub | 2 | GlobeNewswire (USA) | ||
| 09.06. | Aclarion partners with PRIA Healthcare on market access program | 4 | Investing.com | ||
| 09.06. | Aclarion, Inc.: Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform | 424 | GlobeNewswire (Europe) | Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK... ► Artikel lesen | |
| 08.06. | Aclarion Comments on Echo Lake News | 1 | Baystreet.ca | ||
| 08.06. | Aclarion, Inc.: Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal | 872 | GlobeNewswire (Europe) | BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 08.06. | Aclarion, Inc.: Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting | 258 | GlobeNewswire (Europe) | BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 399,00 | -0,86 % | ISRG Sales Jump 22%: Can Growth Stay Ahead of Procedure Volumes? | ||
| UNITEDHEALTH | 367,80 | -0,27 % | UnitedHealth Group To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Tuesday | ||
| THERMO FISHER | 628,40 | -1,44 % | Argus raises Thermo Fisher stock price target on M&A strength | ||
| ATOSSA THERAPEUTICS | 2,120 | +6,53 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| CENTENE | 60,50 | -1,59 % | Centene Posts Narrower Loss In Q3 | WASHINGTON (dpa-AFX) - Centene (CNC) posted a third quarter net loss of $71 million, compared with a net loss of $6.631 billion in the same period a year ago. The company reported diluted loss... ► Artikel lesen | |
| QUIDELORTHO | 12,505 | +1,46 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,230 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| NANO-X IMAGING | 0,303 | -0,88 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| TEMPEST THERAPEUTICS | 0,534 | +0,11 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| FULGENT GENETICS | 18,000 | -7,69 % | Fulgent expects $330M-$340M 2026 revenue as billing transition lowers collection rates | ||
| LANTHEUS | 89,20 | -0,56 % | Lantheus Holdings, Inc.: Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY TruVu (piflufolastat F 18) | BEDFORD, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 1,025 | -2,57 % | XFRA AAJ0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPERSPECT.THER.NEW... ► Artikel lesen | |
| OMNICELL | 33,200 | +0,61 % | Omnicell anticipates $1.225B-$1.231B 2026 revenue while raising non-GAAP EBITDA to $187M-$193M | ||
| AMN HEALTHCARE SERVICES | 42,200 | +0,48 % | AMN Healthcare Services, Inc.: Amn Healthcare Announces Second Quarter 2026 Results | Quarterly revenue of $673 million and adjusted EBITDA of $73 million;
GAAP income of $0.53/share and adjusted EPS of $0.77
DALLAS, Aug. 6, 2026 /PRNewswire/ --... ► Artikel lesen |
ACLARION INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 1,570 Euro und damit -3,09 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.